The extra cost of biologics as first-line treatment in uncontrolled chronic rhinosinusitis with nasal polyps with no previous sinus surgery is overwhelming: a budget impact analysis
At current costs, if biologics were used as a first-line treatment (no previous sinus surgery) in patients with uncontrolled CRSwNP, the extra direct cost would be overwhelming.
Authors
- Thibault Savary
- Jennifer Margier (ORCID: https://orcid.org/0000-0003-2590-4228)
- Florent Carsuzaa (ORCID: https://orcid.org/0000-0001-5574-8559)
- S. Bartier (ORCID: https://orcid.org/0000-0002-5817-691X)
- Jung Hyun Chang (ORCID: https://orcid.org/0000-0003-1000-2491)
- S. Tringali (ORCID: https://orcid.org/0000-0002-3236-4963)
- Valentin Favier (ORCID: https://orcid.org/0000-0002-7999-951X)
- M. Fieux (ORCID: https://orcid.org/0000-0001-8317-2286)
- Peter H. Hwang (ORCID: https://orcid.org/0000-0002-0786-4675)
- Zara M. Patel (ORCID: https://orcid.org/0000-0003-2072-982X)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris-Est Créteil (FR)
- Université de Montpellier (FR)
- Laboratoire d'Informatique, de Robotique et de Microélectronique de Montpellier (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique (FR)
- Institut Mondor de Recherche Biomédicale (FR)
- Stanford University (US)
Publication Details
- Journal
- Rhinology Journal
- Published
- 2025-05-01
- DOI
- https://doi.org/10.4193/rhin24.418
- Citations
- 1
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- Philippe Foundation
- Hospices Civils de Lyon